DEST Destiny Pharma Plc

TIDMDEST

RNS Number : 6865A

Destiny Pharma PLC

25 May 2023

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Result of Annual General Meeting

Brighton, United Kingdom - 25 May 2023 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that all resolutions proposed to shareholders at the Annual General Meeting held earlier today were duly passed.

The full text of each resolution was included in the notice of the meeting which was made available on the Company's website and posted to shareholders on 27 April 2023. The results for the resolutions will shortly be available on the Investors' section of the Company's website, www.destinypharma.com .

For further information, please contact:

Destiny Pharma plc

Dr Debra Barker, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0)20 7220 0500

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

Optimum Strategic Communications

Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper

+44 (0) 203 922 0891

DestinyPharma@optimumcomms.com

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has completed a positive Phase 2 clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV (TM) , a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

   For further information on the Company, please visit   https://www.destinypharma.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGAAMBTMTTTBBJ

(END) Dow Jones Newswires

May 25, 2023 07:23 ET (11:23 GMT)

Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024